COSTEM 2022 | Do CAR-T therapies play a role in earlier lines of therapy in multiple myeloma?
Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, comments on current research assessing CAR-T therapy in earlier settings in multiple myeloma, where they are currently indicated for relapsed or heavily pretreated patients. The Phase III KarMMa-3 trial (NCT03651128) and the Phase II CARTITUDE-2 trial (NCT04133636) have demonstrated the potential of moving CAR-T therapies into earlier lines of therapy. Dr Sonneveld also highlights additional trials investigating CAR-Ts with maintenance bispecific antibodies in multiple myeloma. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda; Advisory Board: Amgen, BMS, Celgene, Janssen, Karyopharm, Takeda.
